Roxane Mari Mathilde Guerin Cécile Vicier Jochen Walz Nathalie Bonnet Géraldine Pignot Gwenaelle Gravis
10.3389/fimmu.2022.984132
Front Immunol
2022 Sep 16;13:984132.
bullous pemphigoid durable response immunotherapy late adverse event renal cell carcinoma
CC BY
https://pubmed.ncbi.nlm.nih.gov/36189265/
Carcinoma, Renal Cell / drug therapy Kidney Neoplasms / drug therapy Kidney Neoplasms / pathology Pemphigoid, Bullous / chemically induced Pemphigoid, Bullous / diagnosis Pemphigoid, Bullous / drug therapy
Carcinoma, Renal Cell / drug therapy Kidney Neoplasms / drug therapy Kidney Neoplasms / pathology Pemphigoid, Bullous / chemically induced Pemphigoid, Bullous / diagnosis Pemphigoid, Bullous / drug therapy Case Reports Aged Humans Immune Checkpoint Inhibitors Male Nivolumab / adverse effects Immune Checkpoint Inhibitors Nivolumab
PMC9524245
36189265
Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report
2022